The gonadotrophin-releasing hormone antagonist ganirelix—History and introductory data

Human Fertility

Volumn 5, Issue 1, 2002, Pages G5-G12

  Out, Henk J ^a   Mannaerts, Bernadette M j l ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NV ORGANON   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BUSERELIN; CHORIONIC GONADOTROPIN; ESTRADIOL; FOLLITROPIN; GANIRELIX; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; LEUPRORELIN; LUTEINIZING HORMONE; PROGESTERONE; RECOMBINANT FOLLITROPIN; TRIPTORELIN;

ADULT; CLINICAL TRIAL; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FERTILIZATION IN VITRO; HEALTH CARE AVAILABILITY; HEALTH PROGRAM; HORMONE BLOOD LEVEL; HUMAN; INFERTILITY; INFERTILITY THERAPY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOMES RESEARCH; OVARY HYPERSTIMULATION; OVULATION INDUCTION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PREGNANCY RATE; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION; STEADY STATE; TREATMENT OUTCOME; TREATMENT PLANNING;

ADOLESCENT; ADULT; BUSERELIN; CLINICAL TRIALS, PHASE III; DOUBLE-BLIND METHOD; FEMALE; FERTILITY AGENTS, FEMALE; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; HUMANS; LEUPROLIDE; MALE; OVULATION INDUCTION; PREGNANCY; TRIPTORELIN;

EID: 0036128455     PISSN: 14647273     EISSN: 17428149     Source Type: Journal    
DOI: 10.1080/1464727992000199771     Document Type: Article

References (18)

1. Baba Y, Matsuo H, Schally V. Structure of the porcine LH- and FSH-releasing hormone. II. Confirmation of the proposed structure by conventional sequential analysis. Biochemical and Biophysical Research Communications 1971; 44: 459 – 463
2. de Jong D, Van Hooren EG, Macklon NS, Mannaerts BMJL, Fauser BCJM. Pregnancy and birth after GnRH agonist treatment for induction of final oocyte maturation in a woman undergoing ovarian stimulation for ICSI, using a GnRH antagonist (Antagon/Orgalutran) to prevent a premature LH surge: a case report. Journal of Assisted Reproduction and Genetics 2001; 18: 30 – 33
3. European and Middle East Orgalutran® Study Group. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Human Reproduction 2001; 16: 644 – 651
4. European Orgalutran® Study Group, Borm G, Mannacrts B. Treatment with the gonadotropin-releasing hormone antagonist ganirelix in women undergoing controlled ovarian hyperstimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. Human Reproduction 2000; 15: 1490 – 1498
5. B.C.J.M., Fauser, D., de Jong, F., Olivennes, H., Wramsby, C., Tay, J., Itskovitz-Eldor, H.G., vanHooren, Endocrine profiles following triggering of final oocyte maturation with gonadotropin-releasing homrone (GnRH) agonist after co-treatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for IVF, Journal of Clinical Endocrinology and Metabolism, in press, (2002), 87
6. Ganirelix Dose-Finding Study Group. A double-blind, randomized, dose-finding study to assess the efficacy of the GnRH antagonist ganirelix (Org 37642) to prevent premature LH surges in women undergoing controlled ovarian hyperstimulation with recombinant FSH (Puregon®). Human Reproduction 1998; 13: 3023 – 3031
7. Itskovitz-Eldor J, Kol S, Mannaerts B, Coelingh Bennink HC. First established pregnancy after controlled ovarian hyperstimulation with recombinant follicle stimulating hormone and the gonadotropin-releasing hormone antagonist ganirelix (Org 37642). Human Reproduction 1998; 13: 294 – 295
8. Itskovitz-Eldor J, Kol S, Mannaerts B. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report. Human Reproduction 2000; 15: 1965 – 1968
9. Kol, S, Lightman, A, Hillensjö, T, et al. High doses of GnRH antagonist in IVF do not adversely affect the outcome of subsequent freeze-thaw cycles. Human Reproduction 1999; 14: 2242 – 2244
10. Lemay, A, Maheux, R, Faure, N, et al. Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LHRH) agonist (Buserelin) as a new therapeutic approach for endometriosis. Fertility and Sterility 1984; 41: 863 – 871
11. Mannaerts B, Gordon K. Embryo implantation and GnRH antagonists. GnRH antagonists do not activate the GnRH receptor. Human Reproduction 2000; 15: 1882 – 1883
12. North American Ganirelix Study Group. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertility and Sterility 2001; 75: 35 – 45
13. Oberyé JJL, Mannaerts BMJL, Kleijn HJ, Timmer CJ. Pharmacokinetic and pharmacodynamic characteristicis of ganirelix (Orgalutran). Part I. Absolute bioavailability of 0.25 mg ganirelix after single subcutaneous injection in healthy female volunteers. Fertility and Sterility 1999a; 72: 1001 – 1005
14. Oberyé JJL, Mannaerts BMJL, Huisman JAM, Timmer CJ. Pharmacokinetic and pharmacodynamic characteristicis of ganirelix (Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers. Fertility and Sterility 1999b; 72: 1006 – 1012
15. Olivennes F, Mannaerts B, Struijs M, Bonduelle M, Devroey P. Perinatal outcome of pregnancy after GnRH antagonist (ganirelix) treatment during ovarian stimulation for conventional IVF or ICSI: a preliminary report. Human Reproduction 2001; 16: 1588 – 1591
16. Porter, RN, Smith, W, Craft, IL, et al. Induction of ovulation for in vitro fertilisation using buserelin and gonadotropins. Lancet 1984; 2: 1284 – 1285
17. Reismann T, Schally AV, Bouchard P, Riethmuller H, Engel J. The LHRH-antagonist Cetrorelix: a review. Human Reproduction Update 2000; 6: 322 – 331
18. Schally AV, Halmos G, Rekasi Z, Arencibia-Jimenez JM. The actions of luteinizing hormone-releasing hormone agonists, antagonists, and cytotoxic analogues on the luteinizing hormone-releasing hormone receptors on the pituitary and tumors. Infertility and Reproductive Medicine Clinics of North America 2001; 12: 17 – 44